SecBot SecBot
8-K ·Filed Apr 13, 2026

XENE

Xenon Pharmaceuticals Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed7mo ago SEC0001193125-26-152834
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for future Form 4 filings to see if any new inducement grants are made under this expanded plan. The increased share reserve provides flexibility for hiring, but does not represent immediate dilution.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$59.35
T+0 close · Apr 13, 2026 · via day close
Latest settled
+19.56%
T+60 · $70.96
Vs SPY
+11.04%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $59.35entry
  2. T+1 · 7mo ago −0.79%α −1.57% · $58.88
  3. T+5 · 7mo ago −4.97%α −6.36% · $56.40
  4. T+20 · 6mo ago −6.02%α −12.31% · $55.78
  5. T+60 · 4mo ago +19.56%α +11.04% · $70.96
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xenon Pharmaceuticals amended and restated its 2025 Inducement Equity Incentive Plan to increase the share reserve from 900,000 to 1,175,000 common shares, to be used exclusively for hiring inducements. This filing is routine and does not involve any new equity grants or executive appointments.

Key Facts

  • Company amended and restated its 2025 Inducement Equity Incentive Plan
  • Increased share reserve from 900,000 to 1,175,000 common shares
  • New shares to be used exclusively for inducement grants to new hires or rehires
  • No shareholder approval required under Nasdaq Listing Rule 5635(c)(4)
  • Filing is administrative and does not involve any new equity grants

Financial Impact

Potential future dilution of up to 1,175,000 shares, but no immediate financial impact as no new grants were issued

dilutionshares outstanding

Risk Factors

  • Potential future dilution if the full share reserve is utilized
  • No immediate risk as no new grants were issued in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-152834
Document: xene-20260407.htm0001193125-26-152834
Document: 0001193125-26-152834-index-headers.html0001193125-26-152834
Document: 0001193125-26-152834-index.html0001193125-26-152834
Document: 0001193125-26-152834.txt0001193125-26-152834

Track record

19 reports on XENE

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
  2. Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
  3. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  4. Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
  5. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
  6. Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
  7. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
  8. Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
  9. Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
  10. Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 8h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026